Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, has announced their merger to form Calluna Pharma. Calluna has raised €75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!